Correctsequence Therapeutics Co., Ltd
Clinical trials sponsored by Correctsequence Therapeutics Co., Ltd, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Gene editing shot aims to tame deadly fat levels in rare disease Results expected Dec 2026 (estimated)
- Gene-Editing breakthrough? new therapy aims to stop sickle cell pain crises Results expected Dec 2026 (estimated)
-
Gene editing offers hope for blood disorder patients
Disease control CompletedThis early-phase study tested a new gene-edited stem cell treatment (CS-101) in 5 people with beta-thalassemia, a severe blood disorder requiring regular blood transfusions. The goal was to see if the treatment is safe and can help patients produce healthy red blood cells, potent…
Early phase 1 • Sponsor: CorrectSequence Therapeutics Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
Gene therapy breakthrough? early trial for blood disorder shows promise
Disease control CompletedThis early-stage study tested a single dose of a gene therapy called CS-101 in 9 people with beta-thalassemia major, a severe blood disorder requiring lifelong transfusions. The main goals were to check safety and see if the treatment helps the body make more healthy hemoglobin. …
Phase 1 • Sponsor: CorrectSequence Therapeutics Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC